Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP – Get Free Report) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 337,919 shares, an increase of 172.8% from the May 31st total of 123,876 shares. Based on an average trading volume of 1,213,060 shares, the days-to-cover ratio is presently 0.3 days. Currently, 27.7% of the shares of the company are sold short.
Aspire Biopharma Stock Performance
Shares of ASBP stock traded down $0.78 during midday trading on Tuesday, reaching $5.36. 66,672 shares of the company were exchanged, compared to its average volume of 425,754. The company’s 50 day moving average price is $5.91 and its two-hundred day moving average price is $43.42. The company has a market cap of $6.96 million, a P/E ratio of -0.05 and a beta of 0.17. Aspire Biopharma has a 12 month low of $3.31 and a 12 month high of $1,050.36.
Aspire Biopharma (NASDAQ:ASBP – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($20.57) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter.
Analyst Ratings Changes
Read Our Latest Research Report on ASBP
Hedge Funds Weigh In On Aspire Biopharma
Several hedge funds have recently modified their holdings of the company. CIBC Bancorp USA Inc. acquired a new stake in shares of Aspire Biopharma in the third quarter valued at $28,000. Jane Street Group LLC grew its holdings in Aspire Biopharma by 625.8% during the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after acquiring an additional 131,533 shares during the period. Finally, XTX Topco Ltd raised its position in Aspire Biopharma by 853.2% in the fourth quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after acquiring an additional 237,620 shares in the last quarter. 19.17% of the stock is currently owned by institutional investors and hedge funds.
About Aspire Biopharma
Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.
The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.
Featured Articles
- Five stocks we like better than Aspire Biopharma
- Volkswagen’s 16-Year Low Masks a Massive Margin Engine
- Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat
- Manchester United’s Stock Rally Faces a Test Beyond Old Trafford
- Overclocking Qualcomm: Rewiring the AI Compute Market
Receive News & Ratings for Aspire Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspire Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
